Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
If FY2027 revenue approaches $70.30 billion and diluted EPS approaches $9.54, a lower share count could lift value per share.
FY2027 provider-adjusted diluted EPS falls below $8.41.
Hold. At $150.33 on 2026-09-04, the shares stood above Fair value of $141.37, so the evidence does not support increasing exposure.3
For an ordinary investor, Hold means keeping an existing position while waiting for stronger evidence on earnings durability and cash funding.
Potential value is $278.92, but it requires sustained revenue, margins and shareholder returns rather than a short rebound.
The main risk is FY2027 diluted EPS below $8.41. That would weaken the profit base and reduce cash available for dividends and debt reduction.1
The clearest upside path is FY2027 revenue near $70.30 billion and EPS near $9.54, supported by fewer shares outstanding.13
A favorable demand cycle would appear if Merck reaches its dated FY2027 revenue forecast and peers maintain growth without forcing pricing concessions.1
Hold because the report-date price is above Fair value and the earnings recovery still needs proof.3
Hold because the report-date price is above Fair value and the earnings recovery still needs proof.3
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders.
The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions.
A combined earnings miss, weaker cash backing and valuation compression would reduce profit durability, shareholder distributions and the price investors pay for future earnings.
Merck has no validated structural moat in the supplied evidence. Profit and cash generation are business outcomes, not proof of switching costs, scale advantages or protected distribution.
The mixed peer set is useful for growth and valuation comparisons. Its members have different margins and growth rates, while the evidence does not establish product-level market-share transfer.
FY2025 profit and positive cash generation show valuable operations, but they do not establish a lasting barrier against competition.4
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($141.37). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $21.1B after modeled capex of $4.1B, with terminal value at 67.7% of . A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Stronger revenue and margins would improve the earnings base.
The pharmaceutical industry benchmark shows capital spending at 1.1% of revenue and 0.8 times depreciation, as of and retrieved 2026-09-01.
A favorable demand cycle would appear if Merck reaches its dated FY2027 revenue forecast and peers maintain growth without forcing pricing concessions.
A weaker cycle would combine slower issuer growth with peer outgrowth and lower valuation benchmarks, pressuring sales, margins and the value assigned to future earnings.
No new target percentage is prescribed; maintain the existing allocation. The report-date price of $150.33 is above Fair value of $141.37, while the valuation range remains wide.3
Keep exposure unchanged unless valuation improves and the earnings floor holds. Reduce on either the EPS or cash-funding breach.
Cash generation supports distributions, but FY2025 debt of $50.53 billion limits flexibility.3
The $150.33 report-date price exceeds Fair value of $141.37, although Potential value remains higher.3
Dated forecasts support recovery through FY2027, but they do not establish prolonged acceleration.1
Hold because the report-date price stands 5.96% above Fair value, while the earnings recovery still requires proof.3
Near-term revenue and EPS forecasts support the business outlook, but leverage, peer pressure and limited visibility after FY2027 restrain the case.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
This path would show that normalization failed to create durable profit. Weaker cash funding and valuation compression would compound the effect.
If FY2027 diluted EPS falls below $8.41, the rebound would sit outside the dated estimate range and weaken the normalized earnings base.1
If operating cash drops below $0.80 for each $1.00 of reported profit, dividend funding and cash-based valuation support would weaken.
If the forward price-to-earnings ratio falls below 12.8 times within 24 months, investors would pay less for each dollar of expected earnings.
The five developments that would weaken our investment case.
A miss would show the earnings rebound is not durable, lowering the profit base used to support future cash and dividends.
Current:Analyst mean of $9.54, with an $8.41–$10.36 range for FY2027, as of and retrieved 2026-09-08.
Alert ifBelow $8.41 in FY2027.
Stagnation would stop the operating base from expanding, limiting fixed-cost absorption and weakening later profit, cash generation and value per share.
Current:FY2027 analyst revenue mean of $70.30 billion, as of and retrieved 2026-09-08.
Alert ifFY2028–FY2030 average consolidated revenue growth below 0%.
Lower cash backing for reported profit would weaken dividend coverage, debt reduction and the ability of earnings to fund shareholder returns.
Current:FY2025 produced $0.90 of operating cash for each $1.00 of reported profit.
Alert ifBelow $0.80 within 12 months.
Compression would reduce what investors pay for each dollar of expected profit, even if the business still posts modest revenue growth.
Current:15.72 times next-twelve-month earnings as of and retrieved 2026-09-08.
Alert ifBelow 12.8 times within 24 months.
Persistently high debt would redirect cash toward interest and repayment, leaving less for dividends, repurchases and future per-share growth.
Current:FY2025 debt was $50.53 billion and cash was $14.57 billion; both were retrieved 2026-09-08.
Alert ifFY2027 debt remains at or above the FY2025 level while cash generation weakens.
| Threat | Severity | Timeline | Mitigation |
|---|
| Faster broad-pharma growth could attract demand and investment away from Merck, while pricing pressure could reduce sales and margins. | high | Through FY2027 and the following two fiscal years | Require Merck to meet the dated FY2027 revenue forecast without margin erosion before assuming a longer advantage period.1 |
| A forward valuation reset would make investors pay less for each dollar of expected earnings, even if revenue continues growing modestly. | medium | Within 24 months | Keep valuation expectations tied to demonstrated earnings normalization rather than assume a premium to the observed comparable range. |
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Limitation: Terminal value is 81% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
Solve for the growth rate that makes the model value equal the report-date share price.
Revenue recovery continues, margins normalize and per-share results receive modest support from a lower share count. Later growth remains measured rather than accelerating.3
Upside persists if growth and margins last beyond the rebound. It fades if stronger results require more investment or debt than operating cash can fund.
That combination would undermine profit durability and distributions.
Cash backing remains supportive, but disagreement between forensic accounting observations argues for continued verification rather than treating reported profit as unquestioned.
The rebound must establish a durable earnings base.1
Margin durability determines how sales convert into profit.
Weaker backing would restrict dividends and debt reduction.
| $48.70B |
| $59.28B |
| $60.12B |
| $64.17B |
| $65.01B |
| +7.5% |
| Gross profit | $35.08B | $41.87B | $43.99B | $48.98B | $46.73B | +7.4% |
| Operating income | $14.69B | $17.41B | $3.04B | $21.21B | $22.42B | +11.2% |
| Net income | $13.05B | $14.52B | $365.0M | $17.12B | $18.25B | +8.8% |
| EPS (diluted) | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 | +9.1% |
| EBITDA | $17.90B | $21.32B | $6.91B | $25.71B | $28.26B | +12.1% |
| R&D | $12.25B | $13.55B | $30.53B | $17.94B | $15.79B | +6.6% |
| SG&A | $9.63B | $10.04B | $10.50B | $10.82B | $10.73B | +2.7% |
FY2025 operating cash gave substantial support to reported profit, although conflicting forensic evidence warrants continued verification.
Shares outstanding were 2.467 billion on 2026-09-08, below the FY2025 diluted average of 2.507 billion. Continued per-share gains depend on funding repurchases without raising leverage.
Use the dated revenue, profit, capital spending and leverage evidence rather than infer a capital-efficiency trend from an unmatched snapshot.
Treat the comparison as unknown. The dated WACC was 6.601% as of and retrieved 2026-09-08.
Revenue was $65.01 billion and net income was $18.25 billion for FY2025, retrieved 2026-09-08.
The base supports recovery, but the wide FY2027 earnings range shows that durability still needs proof.
FY2025 capital spending was $4.11 billion, while debt exceeded cash.
More cash may need to fund investment and debt reduction before supporting faster dividends or repurchases.
| Revenue | $65,011,000,000 |
|---|---|
| Cost of revenue | $18,280,000,000 |
| Gross profit | $46,731,000,000 |
| Operating expenses | $23,245,000,000 |
| Operating income | $23,486,000,000 |
| Non-operating items and tax | -$5,232,000,000 |
| Net income | $18,254,000,000 |
| Total assets | $136,866,000,000 |
|---|---|
| Cash | $14,565,000,000 |
| Current assets | $43,516,000,000 |
| Total liabilities | $84,204,000,000 |
| Current liabilities | $28,327,000,000 |
| Shareholders’ equity | $52,662,000,000 |
| Net income | $18,254,000,000 |
|---|---|
| Operating inflow | $24,912,000,000 |
| Depreciation and amortization | $5,838,000,000 |
| Stock-based compensation | $820,000,000 |
| Operating cash flow | $16,472,000,000 |
| Operating outflow | $8,440,000,000 |
| Cash available | $30,353,000,000 |
| Beginning cash | $13,318,000,000 |
| Exchange-rate effect | $563,000,000 |
| Investing outflow | $13,741,000,000 |
| Capex | $4,112,000,000 |
| Other investing activities | $9,629,000,000 |
| Financing outflow | $1,922,000,000 |
| Net debt issuance | $11,377,000,000 |
| Share repurchases | $5,084,000,000 |
| Dividends paid | $8,176,000,000 |
| Other financing activities | $39,000,000 |
| Ending cash | $14,690,000,000 |
| Investing cash flow | -$13,741,000,000 |
| Financing cash flow | -$1,922,000,000 |
Point-in-time financial data used in the 2026-09-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $39.8B | $10.8B | $3.9B | $10.4B | $8.8B | $1.6B | $5.5B | $300M | $3.4B | $5.1B | — | -$3.2B | -$9B | — | $6.5B | $14.3B | $24.8B | 13.8% | — | 5.5% | — |
| 2017-12-31 | $40.1B | $12B | $2.4B | $6.5B | $4.6B | $1.9B | $4.7B | $312M | $4B | $5.2B | — | $2.7B | -$10B | $6.5B | $6.1B | $8.5B | $24.4B | 16.9% | — | 5.2% | — |
| 2018-12-31 | $42.3B | $14B | $6.2B | $10.9B | $8.3B | $2.6B | $4.5B | $348M | $9.1B | $5.2B | — | $4.3B | -$13.2B | $6.1B | $8B | $8.9B | $25.1B | 21.1% | — | 5.9% | — |
| 2019-12-31 | $39.1B | $11.4B | $9.8B | $13.4B | $10.1B | $3.4B | $3.7B | $388M | $4.8B | $5.7B | — | -$2.6B | -$8.9B | $8B | $9.9B | $10.5B | $27.4B | 20.3% | — | 5.1% | — |
| 2020-12-31 | $41.5B | $10.2B | $7.1B | $10.3B | $5.8B | $4.4B | $3.6B | $441M | $1.3B | $6.2B | — | -$9.4B | -$2.8B | $9.9B | $8.2B | $8.1B | $33.4B | 13.4% | — | 3.5% | — |
| 2021-12-31 | $48.7B | $17.9B | $13B | $14.1B | $9.7B | $4.4B | $3.2B | $479M | $840M | $6.6B | — | -$16.6B | $2.6B | $8.2B | $8.2B | $8.1B | $34.6B | 27.1% | — | 4.2% | — |
| 2022-12-31 | $59.3B | $21.3B | $14.5B | $19.1B | $14.7B | $4.4B | $3.9B | $541M | $0 | $7B | -$2.3B | -$5B | -$9.1B | $8.2B | $12.8B | $13.2B | $32B | 30.8% | — | 6.4% | — |
| 2023-12-31 | $60.1B | $6.9B | $365M | $13B | $9.1B | $3.9B | $3.9B | $645M | $1.3B | $7.4B | $4.2B | -$14.1B | -$4.8B | $12.8B | $6.9B | $7.1B | $36.3B | 4.9% | — | 6.1% | — |
| 2024-12-31 | $64.2B | $25.7B | $17.1B | $21.5B | $18.1B | $3.4B | $4.5B | $761M | $1.3B | $7.8B | $2.3B | -$7.7B | -$7B | $6.9B | $13.3B | $13.7B | $38.3B | 31.5% | — | 6.9% | — |
| 2025-12-31 | $65B | $28.3B | $18.3B | $16.5B | $12.4B | $4.1B | $5.8B | $820M | $5.1B | $8.2B | $11.4B | -$13.7B | -$1.9B | $13.3B | $14.7B | $14.6B | $50.5B | 36.1% | — | 6.4% | — |
Merck & Co. Inc. (MRK) trades at 15.7x forward earnings against a peer median of 12.5x. Its EV/EBITDA of 14.5x compares with a peer median of 11.8x. The comparison uses 4 peers: AbbVie Inc., Pfizer Inc., Gilead Sciences Inc. and Sanofi, as of 2026-07-26 to 2026-09-08.
| Low-single-digit issuer growth | neutral | Dated annual forecasts support expansion through FY2027, but later growth depends on extrapolation rather than another dated demand anchor. |
| Broad-pharma growth dispersion | negative | Comparable revenue growth ranges from 2.6% to 10.2%, increasing execution and valuation pressure on a slower-growing issuer. |
Merck is positioned for moderate recovery rather than industry-leading growth. Sustained margins and cash-funded shareholder returns must offset faster peer growth.1
| Reassess the Hold; do not add automatically. |
| A lower valuation must coincide with evidence that the earnings floor and cash funding remain intact. |
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Limitation: Terminal value is 67.7% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
| Pfizer Inc. |
| 9.8x |
| 2.5x |
| 8.4x |
| 5.0% |
| 27.9% |
| GILD | Gilead Sciences Inc. | 15.3x | 6.1x | 14.3x | -20.7% | 33.7% |
| SNY | Sanofi | 8.4x | 2.2x | 9.3x | 6.6% | 20.0% |
